clinical development

Opus Genetics secures $155M non-dilutive funding from Oberland Capital, extending cash runway through 2029 and accelerating gene therapy development for inherited retinal diseases.

DBV Technologies reports 296M shares outstanding and 296M voting rights as of March 31, 2026, with updates on VIASKIN® Peanut Patch clinical programs.

DBV Technologies files 2025 annual report disclosing 296M shares outstanding, 295.9M voting rights as VIASKIN Peanut development continues.

Celldex prices $300M stock offering at $29/share to fund commercial launch of CSU treatment and expand bispecific antibody platform.

Ardelyx appoints Dr. Rajani Dinavahi, veteran biotech executive from Amgen and Atara Biotherapeutics, as Chief Medical Officer to lead clinical strategy and pipeline advancement.

Agios insider Krishnan sells $82K in shares via routine RSU tax-withholding event. Retains 16,200 unvested RSUs and recent equity grants signal confidence amid PYRUKYND's 86% revenue growth.

Recursion expands Citeline partnership to integrate real-world data into its AI drug discovery platform, achieving 30-60% trial enrollment improvements.

SCYNEXIS completes acquisition of PXL-770 AMPK activator for ADPKD treatment. Deal includes $8M upfront, up to $188M milestones; Phase 2 study planned for late 2026.

Galapagos and Gilead form binding collaboration on gamgertamig, an autoimmune T cell engager, with Galapagos receiving 50% of Gilead's $1.675B Ouro Medicines acquisition.

Damora Therapeutics appoints Jennifer Jarrett as CEO, grants her 2M share awards. Company also awards equity to four new employees under Nasdaq inducement rules.

Novartis to acquire private biotech Excellergy for up to $2B, adding next-generation anti-IgE antibody Exl-111 targeting food allergy, chronic urticaria, and allergic asthma.

iDEL Therapeutics appoints Dr. Claudia Ulbrich as Board Chair and secures €9M seed funding led by BiomedVC to advance its novel cancer drug delivery platform.

Galapagos and Gilead are in advanced partnership talks for a first-in-class T-cell engager for autoimmune diseases, with 50% cost-sharing and €500 million capital freed for Galapagos.

Anaveon appoints veteran biotech executive Thaminda Ramanayake as CEO to guide lead candidate ANV200 through clinical development for autoimmune and inflammatory diseases.

HUTCHMED initiates Phase III trial of HMPL-760 for relapsed/refractory lymphoma in China, enrolling 240 patients following positive Phase II results.

Amphista Therapeutics appoints new CEO and CMO ahead of planned AMX-883 IND application in April 2026 for acute myeloid leukemia treatment.

R1 Therapeutics raised $77.5M in oversubscribed Series A funding to advance AP306, a first-in-class treatment for hyperphosphatemia in chronic kidney disease patients.

Olema reported strong trial progress for palazestrant in breast cancer, raised $218.5M, and expects pivotal data in fall 2026.

Lifeward gains shareholder approval for strategic Oramed deal, securing up to $47M capital while expanding into oral delivery technology.

Cadrenal's 12-LOX inhibitor CAD-1005 shows preclinical promise for obesity and diabetes inflammation reduction, potentially complementing GLP-1 medications.